Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial

Autor:	Zuraw, Bruce, Lumry, William R., Johnston, Douglas T., Aygören-Pürsün, Emel, Banerji, Aleena, Bernstein, Jonathan A., Christiansen, Sandra C., Jacobs, Joshua S., Sitz, Karl V., Gower, Richard G., Gagnon, Remi, Wedner, H. James, Kinaciyan, Tamar, Hakl, Roman, Hanzlíková, Jana, Anderson, John T., McNeil, Donald L., Fritz, Stephen B., Yang, William H., Tachdjian, Raffi, Busse, Paula J., Craig, Timothy J., Li, H. Henry, Farkas, Henriette, Best, Jessica M., Clemons, Desiree, Cornpropst, Melanie, Dobo, Sylvia M., Iocca, Heather A., Kargl, Deborah, Nagy, Eniko, Murray, Sharon C., Collis, Phil, Sheridan, William P., Maurer, Marcus, Riedl, Marc A.
Zdroj:	In The Journal of Allergy and Clinical Immunology July 2021 148(1):164-172
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect